Patent Application
20090131340
1. Field of the Invention
The present invention relates to active compounds and formulations comprising such active compounds for cosmetic or dermatological treatment and/or prophylaxis of inflammatory, allergic or autoimmune-reactive symptoms, and protecting cells which participate in the immune response of the skin.
2. Discussion of Background Information
As a barrier organ in the human organism, the skin, especially the epidermis, is particularly subjected to external effects. According to current scientific understanding, the skin represents an immunological organ which, as an immunocompetent peripheral compartment, plays its own role in inductive, effective and regulatory immune processes of the total organism.
Light occupies an important position among the physical environmental influences. The damaging effect of the ultraviolet component of solar radiation on the skin is generally known. While rays having a wavelength below 290 nm (the so-called UVC range) are absorbed by the ozone layer in the earth's atmosphere, rays in the range between 290 and 320 nm, the so-called UVB range, cause erythema, simple sunburn or even burns of greater or lesser severity. The narrower range around 308 nm is stated as a maximum for the erythema activity of sunlight.
Ultraviolet light from the wavelength range between about 320 and 400 nm (UVA range) can also cause secondary damage to the skin. It has thus been proved that UVA radiation also leads to damage to the elastic and collagenic fibres of connective tissue, which causes the skin to age prematurely (so-called photoageing), and that it is to be regarded as a cause of numerous phototoxic toxic and phototoxic and photoallergic reactions. The damaging influence of UVB radiation may be intensified by UVA radiation.
UVB radiation is of particular interest in the development of topical sunscreen compositions, since the action spectrum for the acutely inflammatory processes (sunburn) and chronic damage (photoageing) is located here.
In addition to these effects, a serious change in the intraepidermal immunological situation may furthermore occur under the action of UVB, this being called UVB-induced immunosuppression. Under certain circumstances, depending on the dose of radiation, far-reaching changes in the immunological processes of the skin with both local and systemic effects are possible consequences here.
Immunosuppression generally is the suppression or attenuation of the reactivity of the immune system. UVB-induced immunosuppression can be classified into local and systemic effects. In the end, it includes a large number of the most diverse aspects, all of which comprise reduction of the normal immunological defense mechanisms of the skin. The increased tumour growth was thus already related to the immunosuppressive action of UVB light very early on using the model of mice irradiated with UVB. This UVB-induced immunosuppresion is nowadays discussed as the mechanism by means of which UVB-induced neoplastic cells, which are in themselves highly immunogenic, withdraw from immunological defense and therefore their own destruction.
There is furthermore a marked decrease in contact hypersensitivity reaction in the case of UVB irradiation compared with some agents which sensitize the skin. The reason for this could lie in a drastic reduction in the number of epidermal Langerhans cells and/or a change in their morphology and functionality. However, Langerhans cells are the afferent arm of the immunological defense of the skin. Effective defense reactions against infectious organisms, such as, for example, Candida albicans or herpes simplex virus, are furthermore absent.
Finally, the expression of “intercellular adhesion molecule-1” on epidermal keratinocytes is suppressed as a consequence of a dermatologically relevant UVB exposure. This glycoprotein on the cell surface (also called ICAM-1) is one of the most important cellular communication structures, via which direct cell-cell contacts between epidermal keratinocytes and leukocytes, such as, for example, T-lymphocytes and monocytes, are regulated.
UVB-induced immunosuppression thus concerns a broad spectrum of immunological dysfunctions which result in a reduction in the defense reactions which normally proceed.
It is indeed customary to use absorbing agents, that is to say the customary light protection substances, against the direct action of ultraviolet radiation.
Derivatives of dibenzoylmethane, for example, are chiefly used for protection against rays in the UVA range.
Many compounds are known for protection against UVB radiation, these chiefly being derivatives of 3-benzylidenecamphor, of 4-aminobenzoic acid, of cinnammic acid, of salicylic acid, of benzophenone and also of 2-phenylbenzimidazole.
It was furthermore also known to employ free radical collectors as agents which act against photo-oxidative symptoms in the skin induced by UV radiation. As is known, such photochemical reaction products are chiefly free-radical compounds, for example hydroxyl radicals or superoxide radical anions. Undefined free-radical photo products which are formed in the skin itself can also show uncontrolled secondary reactions because of their high reactivity. However, singlet oxygen, a non-radical excited state of the oxygen molecule, may also occur under UV irradiation, as may short-lived epoxides and many other reactive oxygen species. Singlet oxygen, for example, is distinguished from the triplet oxygen normally present (free-radical ground state) by an increased reactivity. Nevertheless, excited, reactive (free-radical) triplet states of the oxygen molecule also exist.
It has thus already been proposed to employ vitamin E or vitamin E esters, substances of known antioxidative action, in light protection formulations. However, the background was always UV protection by absorption of light or protection against photo-oxidative processes. Furthermore, the activity of vitamin E from topical vehicles was weak. A high dosage also provided no remedy, since a more prooxidative action was achieved, especially with vitamin E.
Combinations of 2,4-O-furfurylidenesorbitol, thiols and vitamin E, which are mentioned in PCT/DE93/00773, for intensifying the endogenous immune system of the skin have also fallen short of expectations.
The object of the present invention was therefore, and this object is achieved according to the invention, to provide active compounds and formulations comprising such active compounds, with the aid of which
The active compounds and formulations according to the invention act in this way.
It was surprising and not to be foreseen by the expert that the cosmetic or dermatological formulations for treatment and/or prophylaxis of the immunosuppression induced by UVB radiation, characterized by a therapeutically or cosmetically active content of the substance specified below,
and the use of cosmetically or dermatologically acceptable substances specified below for cosmetic or dermatological treatment and/or prophylaxis of the immuno-suppression induced by UVB radiation would achieve these objects.
The substances according to the invention chosen from the group consisting of flavonoids and their glucosides, from the group of cinnamic acid derivatives and from the group of tocopherols and their derivatives are particularly advantageous.
Japanese Laid-Open Specification Hei-06-138,941 indeed describes oral formulations having a content of water-soluble glucosides, which can be chosen, for example, from the group consisting of α-glucosylrutin, α-glucosylmyrictrin, α-glucosylisoquercitrin and α-glucosylquercitrin. Japanese Laid-Open Specification Hei-04-363,395 describes a process for preventing decomposition of perfume constituents which is distinguished, inter alia, by an addition of α-glucosylrutin to the corresponding formulations. European Laid-Open Specification 586 303 and European Laid-Open Specification 595 694 furthermore describe the use of flavonoids as antioxidants or light protection substances in cosmetics. It is furthermore known from U.S. Pat. Nos. 4,144,325 and 4,248,861 and from numerous other documents to employ vitamin E in cosmetic and dermatological light protection formulations. However, the use according to the invention of vitamin E and its derivatives for cosmetic or dermatological prophylaxis of the immunosuppression induced by UVB radiation was not made obvious by the prior art.
However, no indication which could lead in the direction of the present invention is to be found in these specifications.
The above objects are achieved according to the invention.
The invention relates to the use of cosmetic and dermatological formulations having
a) a content of a compound or several compounds from the group consisting of flavonoids or having
b) a content of an active compound combination comprising a compound or several compounds chosen from the group consisting of flavonoids in combination with a compound or several compounds chosen from the group consisting of cinnamic acid derivatives and
c) if appropriate an additional content of a compound or several compounds from the group consisting of antioxidants for treatment or prophylactic treatment of the immunosuppression induced by UVB radiation, in particular for treatment or prophylactic treatment of inflammatory, allergic or autoimmune-reactive symptoms, and for protecting cells which participate in the immune response of the skin.
Active compound combinations b), their use and formulations which comprise these are preferred.
The invention also relates to the use of the active compound according to the invention for the purposes mentioned and their use as immunomodulating or immunoprotective active compounds, in particular in cosmetic and dermatological formulations.
The active compounds and formulations according to the invention are used for protection of immunocompetent cells, such as Langerhans cells, and for protection of cell constituents.
Topical formulations are preferred.
Preferred flavonoids according to the invention are, for example, hydroxylated flavones, flavanones, isoflavones or chalcones, and in each case also glycosides thereof, as well as these non-hydroxylated base structures and parent substances.
The flavonoids according to the invention are also designated A) below, the cinnamic acid derivatives according to the invention are designated B) and the antioxidants according to the invention are also designated C).
According to the invention, the flavonoids A) are preferably chosen from the group consisting of substances of the generic structural formulae
wherein Z1-Z5 independently of one another are chosen from the group consisting of H, OH and O-alkyl, wherein the alkyl groups can be branched and unbranched and can contain 1-10 C atoms, and wherein Gly is chosen from the group consisting of mono- and oligoglycoside radicals, or can also be H. Preferred glycoside radicals are those mentioned below for Gly1-Gly3.
Further flavonoids according to the invention are advantageously chosen from the group consisting of substances of the following formulae:
wherein Z1-Z5 have the abovementioned meanings and Gly1, Gly2 and Gly3 are monoglycoside radicals.
Preferably, Gly1, Gly2 and Gly3 independently of one another are chosen from the group consisting of hexosyl radicals, in particular the rhamnosyl radicals and glucosyl radicals. However, other hexosyl radicals, for example allosyl, altrosyl, apiosyl, arabinosyl, biosidyl, galactosyl, gulosyl, glucoronidyl, idosyl, mannosyl, talosyl and xylosyl, are also advantageously to be used, where appropriate. It may also be advantageous according to the invention to use pentosyl radicals.
It is particularly advantageous in the context of the present invention to choose the flavone glycoside or glycosides from the group consisting of alpha-glucosylrutin, alpha-glucosylmyrictrin, alpha-glucosylisoquercitrin and alpha-glucosylquercitrin.
Compounds such as alpha-glycosylrutin, alpha-glycosylhesperidin, alpha-glycosylnaringin, alpha-mannosylrutin and alpha-rhamnosylrutin are furthermore particularly preferred according to the invention.
It may also be advantageous to omit the above-mentioned glycosidic radicals Gly1-3 and to use the unsubstituted flavonoids (Gly1-3═H), such as, for example, quercitin. It may also be of advantage to use flavonoids in which the glucoside radical is bonded to C7, C4′, C3′ or C5′ via phenolic OH functions.
It may furthermore be advantageous to use flavonoids in which the phenolic OH function on C9 is present in the free form (so-called chalcones). It is particularly advantageous to use neohesperidin dihydrochalcone from this group.
It is advantageous in the context of the present invention to choose the flavonoid or flavonoids from the group consisting of quercitin, rutin, chrysin, kaempferol, myricetin, rhamnetin, apigenin, luteolin, naringin, hesperidin, naringenin, hesperitin, morin, phloridzin, diosmin, fisetin, vitexin, neohesperidin dihydrochalcone, flavone, glycosylrutin and genistein.
The flavonoids which are particularly preferred according to the invention are chrysin, naringin, hesperidin, naringenin, hesperetin, morin, phloridzin, diosmin, neohesperidin dihydrochalcone, flavone and, in particular, alpha-glucosylrutin of the formula
It can furthermore be advantageous in the context of the invention to use commercially available flavonoid-containing plant extracts. These can be aqueous-alcoholic or aqueous-glycolic extracts and dry extracts obtained by the customary methods.
The following extracts have proved to be particularly advantageous: citrous fruit peel or kernel extract (for example Citricidal/Synthapharm), soya extract (for example Phytodermin/Chem. Laboratorium Dr. Kurt Richter GmbH), Sophora japonica extract (for example Sophorine/Solabia), Scotch thistle extract (for example Psoralen Silymarin/Mani GmbH Chemische Produkte), cat's-foot blossom extract, spinach extract and a mixed plant extract of passion flower, blackcurrant and vine leaves (AE Complex/Solabia).
Suitable cinnamic acid derivatives are, for example, hydroxycinnamic acids and derivatives thereof, it being possible for the derivatives to be, for example, those defined below.
Cinnamic acid derivatives of the general formula
and/or active amounts of cinnamic acid derivatives of the general formula
wherein the groups X, Y and R independently of one another can be chosen from the group consisting of H and branched or unbranched alkyl having 1-18 C atoms, can be used according to the invention.
The acids or salts thereof can be used, preferably the physiologically tolerated salts, for example water-soluble salts (sodium or potassium salts).
Ferulic acid is regarded as a particularly advantageous cinnamic acid derivative in the context of the present invention. Ferulic acid (4-hydroxy-3-methoxy-cinnamic acid, caffeic acid 3-methyl ether) is characterized by the structural formula
It is widespread in plants and occurs, for example, in beet crops, cereals and the latex of the umbelliferous plants Ferula asafoetida and Ferula nartex, which give it its name. The E form is a colourless crystalline solid under normal conditions, and the Z form is in the form of a yellowish oil under normal conditions.
In the context of the present invention, it is preferable to use E-ferulic acid. However, it is also advantageous, where appropriate, to employ Z-ferulic acid or any desired mixtures of E- and Z-ferulic acid.
Another derivative of cinnamic acid which is preferred according to the invention is caffeic acid, which is distinguished by the structure
It is a widespread plant acid and is contained, for example, in coffee, tobacco, poppy and dandelion.
It is also advantageous, where appropriate, to use plant extracts with a content of cinnamic acid derivatives according to the invention, in particular ferulic acid and/or caffeic acid.
The term “derivatives of caffeic acid or ferulic acid” is to be understood as meaning their cosmetically or pharmacologically acceptable esters, salts and base adducts, in particular those such as are described above for the cinnamic acid derivatives.
Preferred combinations according to the invention are combinations of one or more substances from the group consisting of the abovementioned flavonoids or combinations of one or more representatives of the flavonoids with a derivative of cinnamic acid, or also the combination with several cinnamic acid derivatives.
Combinations of flavonoids, flavone glucosides or flavonoid-containing plant extracts with ferulic acid and the combination of synthetically modified, in particular glycosylated flavonoids, such as alpha-glycosylrutin, with cinnamic acid derivatives are particularly preferred according to the invention.
The weight ratio of the cinnamic acid derivatives to the flavonoid or flavonoids is advantageously 25:1 to 1:25, preferably 5:1 to 1:5, particularly preferably about 2:1 to 1:2.
Formulations with combinations b) which comprise alpha-glucosylrutin and/or ferulic acid are particularly preferred.
The compounds of group A or those of the combination of active compounds A) and B) can be present as the sole active compounds in the formulations according to the invention.
However, in addition to active compounds A) or the combination of A) and B), the formulations according to the invention can also additionally and preferably have a content of an antioxidant or several antioxidants C).
The antioxidants C) according to the invention can advantageously be chosen from the group consisting of tocopherols and derivatives thereof. The tocopherols, also called vitamin E, are derived from the parent substance tocol (2-methyl-2-(4,8,12-trimethyltridecyl)-chroman-6-ol). The configuration 2R,4′R,8′R is attributed to α-tocopherol, which occurs naturally the most frequently and is the most important. It is occasionally also called RRR-α-tocopherol.
The tocopherol derivatives which are preferred according to the invention are α-tocopherol and its esters, in particular α-tocopheryl acetate. Esters of acids having 2-18, in particular 2-8 C atoms are preferred.
If vitamin E and/or derivatives thereof are the antioxidant or antioxidants, it is advantageous to choose the particular concentrations thereof from the range from 0.001 to 10% by weight, based on the total weight of the formulation.
It is furthermore advantageous to use antioxidants C) from the group consisting of amino acids (for example glycine, histidine, tyrosine and tryptophan) and derivatives thereof, imidazoles (for example urocanic acid) and derivatives thereof, peptides, such as D,L-carnosine, D-carnosine, L-carnosine and derivatives thereof (for example anserine), carotenoids, carotenes (for example α-carotene, β-carotene and lycopene) and derivatives thereof, chlorogenic acid and derivatives thereof, liponic acid and derivatives thereof (for example dihydroliponic acid), aurothioglucose, propyl-thiouracil, thioredoxin and glutathione, and furthermore (metal)chelators (for example α-hydroxy-fatty acids, palmitic acid, phytic acid and lactoferrin), α-hydroxy-acids (for example citric acid, lactic acid and malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and derivatives thereof, unsaturated fatty acids and derivatives thereof (for example γ-linolenic acid, linoleic acid and oleic acid), folic acid and derivatives thereof, ubiquinone and ubiquinol and derivatives thereof, vitamin C and derivatives (for example ascorbyl palmitate, Mg ascorbyl phosphate and ascorbyl acetate), vitamin A and derivatives (vitamin A palmitate) and coniferyl benzoate of benzoin resin, butylhydroxytoluene, butylhydroxyanisole, nordihydroguaiac resin acid, nordihydroguaiaretic acid, trihydroxy-butyrophenone, uric acid and derivatives thereof, mannose and derivatives thereof, mannose and derivatives thereof, sesame oil, sesamolin, zinc and derivatives thereof (for example ZnO and ZnSO4), selenium and derivatives thereof (for example selenium methionine), stilbenes and derivatives thereof (for example stilbene oxide and trans-stilbene oxide) and the derivatives of these active compounds mentioned which are suitable according to the invention (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids).
The amount of the abovementioned antioxidants C) (one or more compounds) in the formulations is preferably 0.001 to 30% by weight, particularly preferably 0.05-20% by weight, in particular 1-10% by weight, based on the total weight of the formulation.
The cosmetic and/or dermatological formulations according to the invention can have the customary composition and can be used for prophylaxis and/or for treatment of the skin in the context of a dermatological treatment or prophylaxis and/or treatment in the context of cosmetics. However, they can also be used in make-up products of decorative cosmetics.
The cosmetic and dermatological formulations according to the invention preferably comprise 0.001% by weight to 30% by weight, preferably 0.01% by weight to 10% by weight, but in particular 0.1% by weight to 6% by weight, based on the total weight, of one or more substances A) according to the invention or of the combination of A) and B).
It is advantageous according to the invention to use combinations of several antioxidants, in particular if at least one of the components is chosen from the group consisting of flavonoids and glucosides thereof and cinnamic acid derivatives.
It is particularly advantageous to use combinations of at least one compound from the flavonoids A) or derivatives thereof, at least one compound from the cinnamic acid derivatives B) and vitamin E or its derivatives C).
It is particularly advantageous to use combinations of synthetically modified, for example glycosylated flavonoids or derivatives thereof, ferulic acid and vitamin E or its derivatives. It is also particularly advantageous to use combinations of naturally occurring flavonoids or derivatives thereof, cinnamic acid and derivatives thereof and vitamin E or its derivatives.
The weight content of active compounds from the group consisting of flavonoids and derivatives thereof and the group consisting of cinnamic acid and its derivatives can be varied in a wide range of ratios in the combinations. The weight ratio of the active compounds is preferably 20:1 to 1:20, in particular 10:1 to 1:10, particularly preferably 2:1 to 1:2.
The weight content of active compounds from the group consisting of flavonoids and derivatives thereof and the group consisting of tocopherol and its derivatives can likewise be varied within a wide range of ratios in the combinations. The weight ratio of the active compounds is preferably 20:1 to 1:20, in particular 10:1 to 1:10, particularly preferably 2:1 to 1:2.
If combinations of active compounds of the group consisting of flavonoids and derivatives thereof and the group consisting of cinnamic acid and its derivatives with the group consisting of tocopherol and its derivatives are used, the weight ratios can preferably be varied within the following limits: 20:1 to 1:20, in particular 10:1 to 1:10, particularly preferably 2:1 to 1:2.
For cosmetic or dermatological treatment and/or prophylaxis of the immunosuppression induced by UVB radiation, for protection of the immunocompetent cells, such as Langerhans cells, and for protection of cell constituents, the formulations according to the invention, preferably combinations of flavonoids and derivatives thereof, cinnamic acid and derivatives thereof and vitamin E and derivatives thereof, are applied to the skin in a sufficient amount in the manner customary for cosmetics or dermatological agents.
Cosmetic formulations according to the invention for protection of the skin can be in various forms, such as are usually employed, for example, for this type of formulation. They can thus be, for example, a solution, an emulsion of the water-in-oil (W/O) type or of the oil-in-water (O/W) type, or a multiple emulsion, for example of the water-in-oil-in-water (W/O/W) type, a gel, a hydrodispersion, an anhydrous ointment, a solid stick or also an aerosol.
The cosmetic formulations according to the invention can comprise cosmetic auxiliaries such as are usually used in such formulations, for example UV/A and UV/B filters, preservatives, bactericides, perfumes, agents for preventing foaming, dyestuffs, pigments which have a colouring action, thickeners, surface-active substances, emulsifiers, softening substances, humidifying and/or humectant substances, fats, oils, waxes or other customary constituents of a cosmetic formulation, such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
If the cosmetic or dermatological formulation is a solution or lotion, solvents which can be used are:
Mixtures of the abovementioned solvents are used in particular. In the case of alcoholic solvents, water can be a further constituent.
Emulsions according to the invention, for example in the form of a sunscreen cream, a sunscreen lotion or a sunscreen milk, are advantageous and comprise, for example, the fats, oils, waxes and other fatty substances mentioned, as well as water and an emulsifier such as is usually used for such a type of formulation.
Gels according to the invention usually comprise alcohols of low C number, for example ethanol, isopropanol, 1,2-propanediol, glycerol and water, or an above-mentioned oil, in the presence of a thickener, which is preferably silicon dioxide or an aluminium silicate in the case of oily-alcohol gels and is preferably a poly-acrylate in the case of aqueous-alcoholic or alcoholic gels.
Anhydrous cosmetic and dermatological formulations, such as ointments or skin oils, according to the invention are advantageous and comprise, for example, the fats, oils, silicone oils, waxes and other fatty sub-stances mentioned.
Solid sticks according to the invention comprise, for example, naturally occurring or synthetic waxes, fatty alcohols or fatty acid esters. Lip care sticks are preferred.
Suitable propellants for cosmetic or dermatological formulations according to the invention which can be sprayed from aerosol containers are the customary known readily volatile, liquefied propellants, for example hydrocarbons (propane, butane and isobutane), which can be employed by themselves or as a mixture with one another. Compressed air can also advantageously be used. The expert of course knows that there are propellant gases which are non-toxic per se and which would be suitable in principle for the present invention, but which should nevertheless be omitted because of an unacceptable action on the environment or other concomitant circumstances, in particular fluorohydrocarbons and fluorochlorohydrocarbons (CFCs).
The formulations according to the invention can furthermore preferably comprise substances which absorb UV radiation in the UVB range, the total amount of the filter substances being, for example, 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, in particular 1 to 6% by weight, based on the total weight of the formulation, in order to provide cosmetic formulations which protect the skin from the entire range of ultraviolet radiation. They can also be used as sunscreen agents.
The UVB filters can be oil-soluble or water-soluble. Oil-soluble substances which may be mentioned are, for example:
Water-soluble substances which may be mentioned are, for example:
The list of UVB filters mentioned, which can be used in combination with the active compounds according to the invention, is not of course intended to be limiting.
The invention also relates to the combination of one or more active compounds according to the invention with one or more UVB filters, and cosmetic or dermatological formulations according to the invention which also comprise one or more UVB filters.
It may also be advantageous to combine one or more active compounds according to the invention with UVA filters which have usually been contained to date in cosmetic and/or dermatological formulations. These substances are preferably derivatives of dibenzoylmethane, in particular 1-(4′-tert-butylphenyl)-3-(4′-methoxyphenyl)propane-1,3-dione and 1-phenyl-3-(4′-isopropylphenyl)propane-1,3-dione. The invention also relates to these combinations and formulations which comprise these combinations. The amounts used for the UVB combination can be employed.
Advantageous formulations are furthermore obtained if the active compounds according to the invention are combined with UVA and UVB filters.
Cosmetic formulations comprising active compounds according to the invention can also comprise inorganic pigments which are usually used in cosmetics for protecting the skin from UV rays. These are oxides of titanium, zinc, iron, zirconium, silicon, manganese, aluminium and cerium and mixtures thereof, as well as modifications in which the oxides are the active agents. The pigments are particularly preferably those based on titanium dioxide.
The invention also relates to these combinations of UVA filters and/or UVB filters and pigment and to formulations which comprise this combination. The amounts mentioned for the above combinations can be used.
Unless stated otherwise, all the amounts data, contents and percentage contents are based on the weight and the total amount or on the total weight of the formulations.
The following examples are intended to illustrate the present invention, without limiting it.
Sophora japonica extract
Sophora japonica extract
The advantageous properties of the present invention are to be illustrated below with the aid of an experiment.
The UVB mixed lymphocyte reaction method (UVB-MLR) was used as the model for the immunosuppressing action of UVB radiation. The UVB-MLR is a method of analyzing the effects of test substances on UVB-induced suppression of a cellular immune response. It is a modification of the MLR, an immunological in vitro standard method which serves as a measure of the activation and functionalization of the T-lymphocyte system.
For this purpose, the test substances were added to the cell cultures in various concentrations. A Phillips TL 20 W/12 lamp was used as the source of irradiation.
7.5 mJ UVB/cm2, 15 mJ UVB/cm2 and 30 mJ UVB/cm2 were employed as the irradiation dose.
Mononuclear cells from the peripheral blood of two healthy human donors are purifed by means of density gradient centrifugation and cultured together in microtitre plates. The individual culture here is composed of 3.0×105 stimulator cells treated with mitocytin (donor A) and 2.5×105 responder cells (donor B) (incubation at 37° C., 7.5% of CO2, 10% of FCS (foetal calf serum) in RPMI 1640 medium).
In a “one way” MLR, the stimulator cells are arrested physiologically by the treatment with mitocytin, so that only they act as a cellular antigen for the responder cells, proliferation of which is determined via the incorporation of 3H-thymidine. The responder cells are no longer recognized as an antigen by the stimulator cells.
The incorporation of 3H-thymidine is analyzed after separation of all the cells, that is to say stimulator and responder cells. The amount of 3H-thymidine incorporated correlates with the ability to give an immune response; the less 3H-thymidine incorporated, the greater the UVB immunosuppression.
In order now to determine the influence of UV light on cell proliferation (responder cells), the stimulator cells are irradiated with the corresponding UVB dose before their incubation with the responder cells. In corresponding parallel batches, the corresponding test substance is present in the culture medium during the irradiation.
Comparisons of the proliferation of the responder cells which can be achieved in the absence and presence of test substances after co-culture with the stimulator cells allow conclusions to be drawn on immunoprotective properties of these substances at the level of UVB-induced immunosuppression.
Agents According to the Invention which were Tested in the Experiment and are Active Against UVB Immunosuppression:
Chrysin, naringen, hesperidin, naringenin, hesperitin, morin, phloridzin, diosmin, neohesperidin dihydrochalcone, flavone, glucosylrutin and cinnamic acid derivatives of the general formula
and/or active amounts of cinnamic acid derivatives of the general formula
wherein the groups X, Y and R independently of one another can be chosen from the group consisting of H and branched or unbranched alkyl having 1-18 C atoms, were used as the test substance.
A significant immunoprotective action was to be observed for all the abovementioned agents according to the invention which were tested and are active against UVB immunosuppression, and for all the three UVB dose values.
| Number | Date | Country | Kind |
|---|---|---|---|
| P 44 44 238.6 | Dec 1994 | DE | national |
The present application is a continuation of U.S. application Ser. No. 08/849,525, the entire disclosure of which is expressly incorporated by reference herein, which is a National Stage of International Application PCT/EP95/04908, filed Dec. 12, 1995, which claims priority of German Patent Application No. 44 44 238.6, filed Dec. 13, 1994.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 08849525 | Aug 1997 | US |
| Child | 12355367 | US |
